Lipoprotein(a) in Vascular Disease, Cancer and Longevity

Chang Gung Medical Journal

Volumn 34, Issue 6, 2011, Pages 555-564

  Wu, June Hsieh ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Apolipoprotein(a); Cancer; Lipoprotein(a); Longevity; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A; APOLIPOPROTEIN B; BETA2 GLYCOPROTEIN 1; DEFENSIN; FIBRONECTIN; INTERLEUKIN 6; LIPOCORTIN 5; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEGALIN; NICOTINIC ACID; SEROTONIN; THROMBOXANE B2; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; VERY LOW DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFECT; FLUSHING; GENE SEQUENCE; GENETIC POLYMORPHISM; HEART DISEASE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LONGEVITY; NEOPLASM; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; VASCULAR DISEASE;

HUMANS; LIPOPROTEIN(A); LONGEVITY; NEOPLASMS; VASCULAR DISEASES;

EID: 84555190627     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbial Scand 1963;59:369-82.
2. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:123-37.
3. Lackner C, Boerwinkle E, Leffert CC, Tahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulse field gel electrophoresis. J Clin Invest 1991;87:2153-61.
4. Frank SL, Klisak I, Sparkes RS, Mohandas T, Tomlinson JE, McLean JW, Lawn RM, Lusis AJ. The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. Hum Genet 1988;79:352-6.
5. 4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci USA 1993;90:11643-7.
6. Becker L, McLeod RS, Marcovina SM, Yao Z, Koschinsky ML. Identification of a crucial lysine residue in apolipoprotein-B100 that mediates noncovalent interaction with apolipoprotein(a). J Biol Chem 2001;276: 36155-62.
7. Becker L, Cook PM, Wright TG, Koschinsky WL. Quantitative evaluation of the contribution of weak lysine-binding sites present with apolipoprotein(a) kringle IV type 6-8 to lipoprotein(a) assembly. J Biol Chem 2004;279:2679-88.
8. Fless GM, Halfman CJ, Kirk EW. The relationship between the effect of lysine analogues and salt on conformation of lipoprotein(a). Biochem 2000;39:2740-7.
9. Weisel JW, Nagaswami C, Woodhead JL, Higazi AAR, Cain WJ, Marcovina SM, Koschinsky ML, Cines DB, Bdeir K. The structure of lipoprotein(a) and ligand induced conformational changes. Biochem 2001;40: 10424-35.
10. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB. The inverse association of plasma lipoprotein concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994;93:2758-63.
11. Bopp S, Köchl S, Acquati F, Magnaghi P, Pethö-Schramm A, Kraft HG, Utermann G, Müller HT, Taramelli R. Ten allelic apolipoprotein[a] 5' flanking fragments exhibit comparable promoter activities in HepG2 cells. J Lipid Res 1995;36:1721-8.
12. Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM. 5' control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci USA 1993;90: 1369-73.
13. Wu JH, Lee IN. Studies of apolipoprotein(a) promoter from subjects with different plasma lipoprotein(a) concentrations. Clin Biochem 2003;36:241-6.
14. White AL, Rainwater DL, Lanford RE. Intracellular maturation of apolipoprotein(a) and assembly of lipoprotein(a) in primary baboon hepatocytes. J Lipid Res 1993;34:509-17.
15. Cox LA, Jett C, Hixson J. Molecular basis of an apolipoprotein[a] null allele: a splice site mutation is associated with deletion of a single exon. J Lipid Res 1998;39: 1319-26.
16. Parson W, Kraft HG, Niederstätter M, Lingenhel AW, Köchl S, Fresser F, Utermann G. A common nonsense mutation in the repetitive kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a). Hum Mutat 2004;24:474-80.
17. White AL, Hixson JE, Rainwater DL, Lanford RE. Molecular basis for "null" lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein level in baboon. J Biol Chem 1994;269:9060-6.
18. Ogorelkova M, Gruber A, Utermann G. Molecular basis of congenital Lp(a) deficiency: a frequent apo(a) "null" mutation in Caucasians. Hum Mol Genet 1999;8:2087-96.
19. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992;360:670-2.
20. Linton MF, Farese RV, Chiesa G, Grass DS, Chin P, Hammer RE, Hobbs HH, Young SG. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest 1993;92:3029-37.
21. Bersot TP, Innerarity TL, Pitas RE, Rall Jr SC, Weisgraber KH, Mahley RW. Fat-feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein(a) and that cause lipid accumulation in macrophages. J Clin Invest 1986;77:622-30.
22. Steyrer E, Durovic S, Frank S, Giebauf W, Burger A, Dieplinger H, Zechner R. The role of lecithin: cholesterol acyltransferase for lipoprotein(a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 1994;94: 2330-40.
23. Islam S, Gutin B, Smith C, Treiber F, Kamboh MI. Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease. Arterioscler Thromb 1994;14:1609-16.
24. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: Evidence for the role the apo(a) gene in coronary heart disease. J Clin Invest 1992;89:1040-6.
25. Wu JH, Kao JT, Wen MS, Wu D. Coronary artery disease risk predicted by lasma concentration of high-density lipoprotein cholesterol, apoprotein A1, apolipoprotein B and lipoprotein(a) in a general Chinese population. Clin Chem 1993;39:209-12.
26. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, Abolafin JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinical Coronary Primary Prevention Trial. JAMA 1994;271:999-1003.
27. Kraft HG, Lingenhel A, Kohl S, Hoppichler F, Kronenberg F, Abe A, Muhlberger V, Schonitzer D, Utermann G. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol 1996;16:713-9.
28. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, Hillis LD, Hobbs HH. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in Afican-American. Arterioscler Thromb Vasc Biol 1995;15:850-5.
29. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-9.
30. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) level and apo(a) size and risk of coronary heart disease in Stanford Five-City project. Arterioscler Thromb Vasc Biol 1997;17:239-45.
31. Craig WY, Neveux LM, Palomaki GE, Cleaveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998;44:2301-6.
32. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease-metaanalysis of prospective studies. Circulation 2000;102:1082-5.
33. Baños-González MA, Peña-Duque MA, Anglés-Cano E, Martinez-Rios MA, Bahena A, Valente-Acosta B, Cardoso-Saldafia G, Angulo-Ortiz J, de la Peña-Diaz A. Apo(a) phenotyping and long-term prognosis for coronary artery disease. Clin Biochem 2010;43:640-4.
34. Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. Lipoprotein(a) binds to fibronectin and has serine protease activity capable of cleaving it. The EMBO J 1989;8:4035-40.
35. Bihari-Varga M, Graber E, Rotheneder M, Zechner R, Kostner GM. Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta. Arterosclerosis 1988;8:851-7.
36. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989;86:3847-51.
37. Malle E, Ibovnik A, Steinmetz A, Kostner GM, Sattler W. Identification of glycoprotein IIb as the lipoprotein(a)-binding protein on platelets. Lipoprotein(a) binding is independent of an Arginyl-Glycyl-Aspartate tripeptide located in apolipoprotein(a). Arterioscler Thromb 1994;14:345-52.
38. Köchl S, Fresser F, Lobentanz E, Baier G, Utermann G. Novel interaction of apolipoprotein(a) with N2 glycoprotein I mediated by the kringle IV domain. Blood 1997;90: 1482-9.
39. Niemeier A, Willnow T, Dieplinger H, Jacobsen C, Meyer N, Hilpert J, Beisiegel U. Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler Thromb Vasc Biol 1999;19:552-61.
40. Vuckovic BA, Djeric MJ, Ilic TA, Canak VB, Kojic-Damjanov SLJ, Zarkov MG, Cabarkapa VS. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients. Srpski Arhiv Za Celokupno Lekarstvo 2010;138 Suppl 1:12-7.
41. Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thromb Res 2010;125:357-61.
42. Edelberg JM, Reilly CF, Pizzo SV. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effect of fibrinogen, heparin, vitronectin and lipoprotein(a). J Biol Chem 1991;266:7488-93.
43. Gonzalez-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: evidence that plasminogen and lipoprotein a compete for the same site. Biochem 1989;29:2374-7.
44. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994;219:21191-7.
45. Fu YC, Yang JT, Chen HW, Wu JH. Effect of lipoprotein(a) on annexin A5 binding to cell membrane. Clinica Chimica Acta 2010;411:1915-9.
46. Kojima S, Harpel PC, Rifkin B. Lipoprotein(a) inhibits the generation of transforming growth factor: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991;113:1439-45.
47. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993;260:1655-8.
48. Sofi F, Marcucci R, Fedi S, Giambene B, Sodi A, Menchini U, Genesin GF, Abbate R, Prisco D. High lipoprotein(a) levels are associated with an increased risk of retinal vein occlusion. Atherosclerosis 2010;210:278-81.
49. Teber S, Deda G, Akar N, Soylu K. Lipoprotein levels in childhood arterial ischemic stroke. Clin & Applied Thromb/Hemostasis 2010;16:214-7.
50. Menendez A, Brett-Finlay B. Defensins in the immunology of bacterial infections. Curr Opin Immunol 2007;19: 385-91.
51. Higazi AAR, Lavi E, Bdeir K, Ulrich AM, Jamieson DG, Rader DJ, Usher DC, Kane W, Ganz T, Cines DB. Defensin stimulates the binding of lipoprotein(a) to human vascular endothelial and smooth muscle cells. Blood 1997;89:4290-8.
52. Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents. Am J Cardiol 2007;100:S53-61.
53. Kagawa A, Azuma H, Akaike M, Janagawa Y, Matsumoto T. Aspirin reduces apolipoprotein(a) (Apo(a) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 1999;274:34111-5.
54. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein and risk of type 2 diabetes. Clin Chem 2010;56:1252-60.
55. Trieu VN, Zioncheck TF, Lawn RM, McConathy WJ. Interaction of apolipoprotein(a) with apolipoprotein Bcontaining lipoprotein. J Biol Chem 1991;266:5480-5.
56. Gries A, Gries M, Wurm H, Kenner T, Ijsseldijk M, Sixma JJ, Kostner GM. Lipoprotein(a) inhibits collageninduced aggregation of thrombocytes. Arterioscler Theomb Vasc Biol 1996;16:648-55.
57. Kokoglu E, Karaarslan I, Karaarslan HM, Baloglu H. Elevated serum Lp(a) levels in the early and advanced stages of breast cancer. Cancer Biochem Biophys 1994;14:133-6.
58. Yang HH, Chen XF, Hu W, Lv DQ, Ding WJ, Tang LI, Jiang JJ, Ye MH. Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer. Clin Chem & Laboratory Med 2009;47:452-7.
59. Jiang J, Nisson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 2006;5:4.
60. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971;285:1182.
61. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Land WS, Cao Y, Sage EH. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell 1994;79: 315-28.
62. O'Reilly MS, Boehm, Shing Y, Fukai N, Vasios G, Lane WS, Birkhead Jr FE, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
63. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem 2005;96:242-61.
64. Knight BL. Lp(a) catabolism in hypercholesterolemic individuals. Chemistry & Physics of Lipids 1994;67-68: 233-9.
65. Angraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipoprotein(a) Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997;100:2170-81.
66. Kostner GM, Wo X, Framk S, Kostner K, Zimmermann R, Steyrer E. Metabolism of Lp(a): assembly and excretion. Clin Genet 1997;52:347-54.
67. Albers JJ, Koschinsky ML, Marcovina SM. Evidence mounts for a role of the kidney in lipoprotein catabolism. Kidney Internat 2007;71:961-2.
68. Reblin T, Donarski N, Fineder L, Brasen JH, Dieplinger H, Thaiss F, Stahol RA, Beisiegel U, Wolf G. Renal handling of human apolipoprotein(a) and its fragments in the rat. Am J Kidney Dis 2001;38:619-30.
69. Schulter V, Koolwijk P, Peters E, Frank S, Hrzenjak A, Graier WF, van Hinsbergh VWM, Kostner GM. Impact of apolipoprotein(a) on in vitro angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:433-8.
70. Hrzenjak A, Frank S, Wo X, Zhou Y, Van Berkel T, Kostner GM. Galactose-specific asialoglycoprotein receptor is involved in lipoprotein(a) catabolism. Biochem J 2003;376:765-71.
71. Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, Tader DJ. Lipoprotein[a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein[a]. J Lipid Res 2005;46:2681-91.
72. Frank S, Hrzenjak A, Blaschitz A, Dohr G, Kostner GM. Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney. Eur J Clin Invest 2001;31:504-12.
73. Yu HK, Kim JS, Lee HJ, Ahn JH, Lee SK, Hong SW, Yoon Y. Suppression of colorectal cancer liver metastasis and extension of survival by expression of apo(a) kringles. Cancer Res 2004;64:7092-8.
74. Kim JS, Yu HK, Ahn JH, Lee HJ, Hong SW, Jung KH, Chang SI, Hong YK, Joe YA, Byun SM, Lee SK, Chung SI, Yoon Y. Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro by interfering with the activation of focal adhesion kinase. Biochem Biophys Res Comm 2004;313:534-40.
75. Trieu VN, Uckun FM. Apolipoprotein(a), a link between atherosclerosis and tumor angiogenesis. Biochem Biophys Res Comm 1999;257:714-8.
76. Lippi G, Franchini M, Salvagno GL, Guidi GC. Lipoprotein[a] and cancer: Anti-neoplastic effect besides its cardiovascular potency. Cancer Treatment Rev 2007;33:427-36.
77. Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherogenesis and thrombosis. Annual Rev Med 1996;47: 423-42.
78. Yano Y, Seishima M, Tokoro Y, Noma A. Stimulatory effects of lipoprotein(a) and low-density lipoprotein on human umbilical vein endothelial cell migration and proliferation are partially mediated by fibroblast growth factor-2. Biochim Biophys Acta 1998;1393:26-34.
79. Ribatti D, Vacca A, Giacchetta F, Cesaretti S, Anichini M, Roncali L, Damacco F. Lipoprotein(a) induces angiogenesis on the chick embryo chorioallantoic membrane. Eur J Clin Invest 1998;28:533-7.
80. Videan EN, Heward CB, Chowdhury K, Plummer J, Su Y, Cutler RG. Comparison of biomarkers of oxidative stress and cardiovascular disease in humans and chimpanzees (Pan troglodytes). Comparative Med 2001;59:287-96.
81. Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Sandhu MS, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Boekholdt SM. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010;56:946-55.
82. Thillet J, Doucet C, Chapman J, Herbeth B, Cohen D, Faure-Delanef L. Elevated lipoprotein(a) levels and small apo(a) isoforms are competitive with longevity. Evidence from a large population of French centenarians. Atherosclerosis 1998;136:389-94.
83. Panza F, D'introno A, Capurso C, Colacicco AM, Seripa D, Pilotto A, Santamato A, Capurso A, Solfrizzi V. Lipoproteins, vascular-related genetic factors, and human longevity. Rejuvenation Res 2007;10:441-58.
84. Matsubara M, Skita H, Shibuya H, Chiba H. Decreased longevity in Japanese men, associated with low-molecular-weight apolipoprotein(a) phenotypes. Annals Clin Biochem 2001;38:120-3.
85. Bergman A, Atzmon G. Ye K, MacCarthy T, Barzilai N. Buffering mechanisms in aging: a system approach toward uncovering the genetic component of aging. PLoS Computational Biol 2007;3:e170.